合成ホルモン市場- 世界の市場規模、シェア、動向、機会、予測、製品別、投与経路別、用途別、エンドユーザー別、地域別、競合別、2020～2030年

合成ホルモンの世界市場は、2024年には5億9,565万米ドルとなり、2030年までのCAGRは12.15%と予測され、予測期間中に力強い成長が見込まれています。

合成ホルモンは、人体に自然に存在するホルモンを実験室で製造したものです。これらのホルモンは内分泌腺で産生されるホルモンの化学構造や機能を模倣していますが、体内ではなく外部で産生されます。合成ホルモンは、ホルモン補充療法（HRT）、避妊、ホルモン関連疾患の治療など、さまざまな医療目的で使用されています。ホルモンバランスの乱れに対処し、ホルモン関連疾患の症状を管理し、避妊を行うためにヘルスケア従事者によって処方されます。合成ホルモンは一般的に、更年期障害、甲状腺機能低下症、ホルモン関連がん、不妊治療などの治療に使用されます。これらのホルモンは、避妊ピル、パッチ、注射、子宮内避妊器具（IUD）などの避妊法にも不可欠です。これらのホルモンは、排卵を抑制し、子宮頸管粘液を濃くし、子宮内膜を変化させて受精卵の着床を防ぐことによって機能します。

先進国を中心とした世界的な高齢化が、合成ホルモン療法の需要に寄与し続けています。

主な市場促進要因

ホルモン関連疾患の有病率の増加

主な市場課題

バイオアイデンティカルホルモンとの競合

バイオアイデンティカルホルモンの保険適用は合成ホルモンに比べて一般的でないことが多く、患者の自己負担額が高くなる可能性があります。

主な市場動向

個別化医療への注目

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の合成ホルモン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（アミノ酸誘導体、ペプチドホルモン、ステロイドホルモン）
  • 投与経路別（静脈内、経鼻、経口、坐薬、局所）
  • 用途別（成長ホルモン欠乏症、男性性腺機能低下症、更年期障害、甲状腺ホルモン欠乏症）
  • エンドユーザー別（病院薬局、オンライン薬局、小売薬局）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の合成ホルモン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の合成ホルモン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の合成ホルモン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の合成ホルモン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの合成ホルモン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の合成ホルモン市場：SWOT分析

第14章 競合情勢

• Acerus Pharmaceuticals Corp.
• American Regent, Inc.
• Anhui Anke Biotechnology（Group）Co. Ltd.
• BioPartners, Inc
• Eli Lilly and Company
• Endo Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• IBSA Institut Biochimique SA
• Lupin Pharmaceuticals, Inc.
• Pfizer, Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Synthetic Hormones Market was valued at USD 595.65 million in 2024 and is expected to experience robust growth during the forecast period, with a projected CAGR of 12.15% through 2030. Synthetic hormones are laboratory-manufactured versions of naturally occurring hormones in the human body. These hormones mimic the chemical structure and functions of those produced by the endocrine glands but are produced externally rather than within the body. Synthetic hormones serve various medical purposes, including hormone replacement therapy (HRT), contraception, and the treatment of hormone-related conditions. They are prescribed by healthcare providers to address hormonal imbalances, manage symptoms of hormone-related disorders, and provide contraception. Synthetic hormones are commonly used in the treatment of conditions such as menopause symptoms, hypothyroidism, hormone-related cancers, and fertility control. These hormones are also integral to contraceptive methods such as birth control pills, patches, injections, and intrauterine devices (IUDs). They function by inhibiting ovulation, thickening cervical mucus, and altering the uterine lining to prevent the implantation of a fertilized egg.

The aging global population, especially in developed countries, continues to contribute to the demand for synthetic hormone therapies.

Key Market Drivers

Increasing Prevalence of Hormonal Disorders

The growing incidence of hormonal disorders is a major driver for the expansion of the global synthetic hormones market. Hormonal imbalances can affect various physiological functions, leading to chronic diseases, reproductive health issues, metabolic disorders, and growth abnormalities. Approximately 60 to 80 million couples globally face infertility challenges, driving the demand for hormone-based treatments and assisted reproductive technologies. In addition, developing nations often experience significant gaps in access to contraception, creating new opportunities for expanded family planning solutions. The lack of safe reproductive healthcare results in 115,000 to 204,000 deaths annually due to unsafe abortion practices, underscoring the urgent need for enhanced healthcare infrastructure and investment in reproductive health services.

As the number of patients diagnosed with hormonal disorders rises, the demand for synthetic hormone therapies has increased. Conditions such as hypothyroidism, adrenal insufficiency, and menopause-related complications require long-term hormone replacement therapy (HRT). Synthetic hormones such as levothyroxine (for thyroid disorders), estrogen and progesterone (for menopause), and corticosteroids (for adrenal gland deficiencies) are essential in managing these conditions. The global population of postmenopausal women is expanding, with women aged 50 and older comprising 26% of the global female population in 2021, up from 22% a decade earlier. This demographic shift, coupled with increasing life expectancy, has led to greater demand for HRT, menopause management, and age-related healthcare innovations.

Diabetes, especially Type 1 diabetes, is another major hormonal disorder, impacting over 425 million people worldwide. With an expected increase in diabetes cases, the demand for synthetic insulin therapies is growing, which is a key segment within the synthetic hormones market. Pharmaceutical companies are investing in advanced insulin formulations and delivery systems, such as long-acting insulin analogs and smart insulin pens, to meet the demand for these therapies. Additionally, infertility due to lifestyle changes, stress, delayed pregnancies, and environmental factors has increased the need for assisted reproductive technologies (ART). Synthetic hormones such as gonadotropins, progesterone, and estrogen are essential in ART procedures like in-vitro fertilization (IVF) and ovulation induction therapies.

Key Market Challenges

Competition from Bioidentical Hormones

Bioidentical hormones, often perceived as more "natural" and less likely to cause adverse effects, present a growing competition to traditional synthetic hormones. Some consumers and healthcare providers prefer bioidentical hormones due to their customization and perceived safety benefits. Bioidentical hormones are often marketed aggressively, highlighting their advantages over synthetic hormones. Additionally, bioidentical hormones may be compounded individually by pharmacies to meet patients' specific needs, further increasing their appeal.

However, bioidentical hormones face different regulatory scrutiny than synthetic hormones and are sometimes classified as dietary supplements rather than pharmaceuticals, potentially leading to variations in quality and safety standards. Despite the ongoing debate about their safety and efficacy, bioidentical hormones may lack the extensive clinical data supporting synthetic hormones. Moreover, their compounded nature can result in variations in formulation and dosage, complicating the establishment of consistent treatment protocols.

Insurance coverage for bioidentical hormones is often less common than for synthetic hormones, which can result in higher out-of-pocket costs for patients.

Key Market Trends

Focus on Personalized Medicine

A key trend in the Global Synthetic Hormones Market is the growing emphasis on personalized medicine. Personalized medicine enables healthcare providers to tailor hormone therapy and dosages based on individual patients' hormonal imbalances, genetics, and responses to treatment. This approach aims to deliver more effective and efficient treatment outcomes, reducing adverse reactions and improving patient safety and compliance. By considering individual factors such as genetic predisposition and response to treatment, personalized medicine helps minimize unnecessary interventions and optimize hormone therapy.

In the treatment of conditions such as menopause or hypogonadism, personalized medicine allows for customized hormone replacement therapy (HRT) that targets the unique needs of each patient, ensuring better symptom relief and hormonal balance. Genetic testing can identify individuals at higher risk for hormone-related disorders or cancers, allowing for early intervention and prevention. Continuous patient monitoring allows for real-time adjustments to treatment plans, improving therapeutic outcomes. Additionally, personalized medicine can guide treatment decisions for hormone-related cancers, such as breast and prostate cancer, by identifying patients most likely to benefit from specific synthetic hormone therapies.

Key Market Players

• Acerus Pharmaceuticals Corp.
• American Regent, Inc.
• Anhui Anke Biotechnology (Group) Co. Ltd.
• BioPartners, Inc.
• Eli Lilly and Company
• Endo Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• IBSA Institut Biochimique SA
• Lupin Pharmaceuticals, Inc.
• Pfizer, Inc.

Report Scope

This report segments the Global Synthetic Hormones Market into the following categories, in addition to detailing the industry trends:

Synthetic Hormones Market, by Product:

• Amino Acid Derivatives
• Peptide Hormones
• Steroid Hormones

Synthetic Hormones Market, by Route of Administration:

• Intravenous
• Nasal
• Oral
• Suppository
• Topical

Synthetic Hormones Market, by Application:

• Growth Hormone Deficiency
• Male Hypogonadism
• Menopause
• Thyroid Hormone Deficiency

Synthetic Hormones Market, by End-User:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Synthetic Hormones Market, by Region:

• North America (United States, Canada, Mexico)
• Asia-Pacific (China, India, South Korea, Australia, Japan)
• Europe (Germany, France, United Kingdom, Spain, Italy)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

The report provides detailed company profiles of the major players in the Global Synthetic Hormones Market.

Available Customizations:

This Global Synthetic Hormones Market report offers customizations to meet specific company needs. The following options are available:

• Company Information: Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Synthetic Hormones Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Amino Acid Derivatives, Peptide Hormone, Steroid Hormones)
  • 5.2.2. By Route of Administration (Intravenous, Nasal, Oral, Suppository, Topical)
  • 5.2.3. By Application (Growth Hormone Deficiency, Male Hypogonadism, Menopause, Thyroid Hormone Deficiency)
  • 5.2.4. By End User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Synthetic Hormones Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Route of Administration
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Synthetic Hormones Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Synthetic Hormones Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Synthetic Hormones Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Synthetic Hormones Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Route of Administration
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Synthetic Hormones Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Synthetic Hormones Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Synthetic Hormones Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Synthetic Hormones Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Synthetic Hormones Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Synthetic Hormones Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Route of Administration
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Synthetic Hormones Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Synthetic Hormones Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Synthetic Hormones Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Synthetic Hormones Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Synthetic Hormones Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Synthetic Hormones Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Route of Administration
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Synthetic Hormones Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Synthetic Hormones Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Synthetic Hormones Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Synthetic Hormones Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Route of Administration
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Synthetic Hormones Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Synthetic Hormones Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Synthetic Hormones Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Synthetic Hormones Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Acerus Pharmaceuticals Corp.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. American Regent, Inc.
• 14.3. Anhui Anke Biotechnology (Group) Co. Ltd.
• 14.4. BioPartners, Inc
• 14.5. Eli Lilly and Company
• 14.6. Endo Pharmaceuticals, Inc.
• 14.7. F. Hoffmann-La Roche Ltd.
• 14.8. IBSA Institut Biochimique SA
• 14.9. Lupin Pharmaceuticals, Inc.
• 14.10.Pfizer, Inc

15. Strategic Recommendations

16. About Us & Disclaimer